Accuhaler product correction

GSK issues product correction for six batches of its Flixotide and Pavtide Accuhalers  The Therapeutic Goods Administration (TGA) has announced that sponsor, GSK Australia, has identified that “a small number” of accuhaler devices for its Flixotide and Pavtide medications may not automatically reload.   The company noted that the accuhalers contain a dry respiratory product for 60 doses, with each dose delivered using a patient-activated